A
CADL icon

AlphaQuest’s Candel Therapeutics CADL Stock Holding History

AlphaQuest’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,941
Closed -$67.5K – 329
2025
Q4 		$67.5K Hold
11,941
– – ﹤0.01% 1865
2025
Q3 		$60.9K Hold
11,941
– – ﹤0.01% 1877
2025
Q2 		$60.4K Buy
11,941
+1,071
+10% +$5.51K 0.01% 1581
2025
Q1 		$61.4K Buy
+10,870
New +$88.8K 0.01% 1466

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaQuest's CADL Position: Q1 2026 in Review

AlphaQuest sold out of Candel Therapeutics (CADL) in Q1 2026, closing a stake of 11,941 shares — an estimated $67.5K sold.

AlphaQuest first reported a position in CADL in Q1 2025 and held it in 4 quarters. The position peaked at $67.5K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • AlphaQuest reported no remaining Candel Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 11,941 Candel Therapeutics shares in Q1 2026, an estimated $67.5K.
  • AlphaQuest first reported a position in Candel Therapeutics in Q1 2025 and held it in 4 quarters.
  • AlphaQuest's Candel Therapeutics position peaked at $67.5K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.